Command Palette

Search for a command to run...

SMSPHARMA

276+0.49%
Market Cap
₹2,573.56 Cr
Stock P/E
35.18
ROCE
12.55%
ROE
11.91%
Book Value
₹75.38

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

POSITIVES
  • FY25 was a landmark year with strong earnings growth.
  • Q4 revenue rose 43% YoY to 248 crore, signaling demand recovery.
NEGATIVES
  • Inventory levels remain elevated due to high-volume, commodity APIs; plan to reduce库存.
  • Slow-moving and older inventory (e.g., HCQ) persists with liquidation plans.

Peers Summary

Sector Leader

SMS Pharmaceuticals Ltd. shows promising growth metrics but is positioned within a competitive landscape where peers excel in profitability and efficiency. The company demonstrates solid revenue growth, yet its valuation metrics suggest it may be on the higher end compared to some peers with stronger margins and lower valuations.

Key Points
  • SMS Pharmaceuticals shows the highest revenue growth YoY (35.86%) among its peers.
  • Cipla Ltd. stands out with the best profitability metrics, including ROE (16.63%) and ROA (13.59%).
  • Divi's Laboratories and Sun Pharmaceuticals are considered overvalued based on high PE and PBV ratios.
Top Performers
Cipla Ltd.

Best profitability metrics, solid revenue growth, and attractive PE ratio.

Dr. Reddy's Laboratories Ltd.

Strong ROE and ROCE while maintaining low debt levels.

Mankind Pharma Ltd.

High revenue growth trajectory and robust profitability ratios.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.